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Access to catheterisation facilities in patients admitted with acute
coronary syndrome: multinational registry study
Frans Van de Werf, Joel M Gore, Álvaro Avezum, Dietrich C Gulba, Shaun G Goodman, Andrzej Budaj, David Brieger,
Kami White, Keith A A Fox, Kim A Eagle, Brian M Kennelly, for the GRACE Investigators
Abstract
Objective To investigate the relation between access to a
cardiac catheterisation laboratory and clinical outcomes in
patients admitted to hospital with suspected acute coronary
syndrome.
Design Prospective, multinational, observational registry.
Setting Patients enrolled in 106 hospitals in 14 countries
between April 1999 and March 2003.
Participants 28 825 patients aged ≥ 18 years.
Main outcome measures Use of percutaneous coronary
intervention or coronary artery bypass graft surgery, death,
infarction after discharge, stroke, or major bleeding.
Results Most patients (77%) across all regions (United States,
Europe, Argentina and Brazil, Australia, New Zealand, and
Canada) were admitted to hospitals with catheterisation
facilities. As expected, the availability of a catheterisation
laboratory was associated with more frequent use of
percutaneous coronary intervention (41% v 3.9%, P < 0.001)
and coronary artery bypass graft (7.1% v 0.7%, P < 0.001). After
adjustment for baseline characteristics, medical history, and
geographical region there were no significant differences in the
risk of early death between patients in hospitals with or without
catheterisation facilities (odds ratio 1.13, 95% confidence
interval 0.98 to 1.30, for death in hospital; hazard ratio 1.05,
0.93 to 1.18, for death at 30 days). The risk of death at six
months was significantly higher in patients first admitted to
hospitals with catheterisation facilities (hazard ratio 1.14, 1.03 to
1.26), as was the risk of bleeding complications in hospital (odds
ratio 1.94, 1.57 to 2.39) and stroke (odds ratio 1.53, 1.10 to
2.14).
Conclusions These findings support the current strategy of
directing patients with suspected acute coronary syndrome to
the nearest hospital with acute care facilities, irrespective of the
availability of a catheterisation laboratory, and argue against
early routine transfer of these patients to tertiary care hospitals
with interventional facilities.
Introduction
The optimal early management of patients presenting to hospi-
tal with acute coronary syndrome has been studied extensively
over the past 10 years. Recent randomised trials and
meta-analyses have shown better clinical outcomes in patients
assigned to an early invasive strategy, including primary percuta-
neous coronary intervention for those with persistent ST
segment elevation,1 or early revascularisation with percutaneous
coronary intervention or coronary artery bypass grafting in
those with non-ST segment elevation acute coronary
syndrome.2–4 In these randomised trials a reduction in recurrent
ischaemic events was consistently associated with the invasive
strategy, while significant reductions in mortality were rarely
observed. For example, in the latest study—the randomised inter-
vention trial of unstable angina (RITA-3)—there was a 34%
reduction in the risk of death, reinfarction, or refractory angina
in the invasive group at four months, mainly due to a halving of
the rise of refractory angina but without any survival benefit.4
In the “real world” the choice of a management strategy is
often governed by the facilities available at the hospital at which
patients initially present. Though thrombolytic and antithrom-
botic therapies are widely available, only 20% of emergency care
departments have access to a catheterisation laboratory, and still
fewer hospitals have the capability to perform immediate percu-
taneous coronary intervention or coronary artery bypass
grafting.5 The issue of whether access to interventional facilities
affects clinical outcomes in patients admitted with acute
coronary syndrome is under scrutiny. A positive association
between the availability of a catheterisation laboratory and
improved outcomes would argue for a change in the routing of
patients with acute coronary syndrome from the nearest
community hospital to a regional specialised tertiary care hospi-
tal with immediate access to a catheterisation laboratory (similar
to the handling of acute trauma cases).6
The global registry of acute coronary events (GRACE) is an
ongoing, multinational, prospective registry of patients with the
entire spectrum of acute coronary syndrome. The registry
collects data on baseline characteristics, management, and clini-
cal outcomes. We investigated the relation between access to a
cardiac catheterisation laboratory and the use of percutaneous
coronary intervention or coronary artery bypass grafting and
clinical outcomes in patients admitted with suspected acute
coronary syndrome.
Methods
Full details of the methods have been published previously.7–9
The global registry is designed to reflect an unbiased population
of patients with acute coronary syndrome, irrespective of
geographical region. A total of 106 hospitals located in 14 coun-
tries contributed data to this analysis.
Patients entered in the registry had to be at least 18 years old,
be admitted with a presumed diagnosis of acute coronary
See bmj.com for three tables of additional data on baseline characteristics
and use of revascularisation procedures in the three diagnostic subgroups
and on regional differences in availability of catheterisation laboratories.
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syndrome (that is, have symptoms consistent with acute
ischaemia), and have at least one of the following: electrocardio-
graphic changes consistent with acute coronary syndrome, serial
increases in serum biochemical markers of myocardial necrosis,
or documentation of coronary artery disease. The qualifying
acute coronary syndrome must not have been precipitated by
non-cardiovascular comorbidity (for example, anaemia or
surgery). At about six months after discharge from hospital,
patients were followed up by telephone, clinical visits, or through
calls to their primary care physician to ascertain the occurrence
of selected long term study outcomes.10
To ensure the enrolment of an unbiased population, each
month we recruited the first 10 to 20 eligible consecutive
patients from each site. We collected data on demographic char-
acteristics, medical history, presenting symptoms, time from
onset of symptoms to admission, biochemical and electrocardio-
graphic findings, treatment practices, and various hospital
outcomes. We used standardised definitions of all variables
related to patients, clinical diagnoses, and hospital complications
and outcomes. All cases were assigned to ST segment elevation
myocardial infarction, non-ST segment elevation myocardial inf-
arction, or unstable angina.
Patients were diagnosed with ST segment elevation myocar-
dial infarction when they had new or presumed new ST segment
elevation ≥ 1 mm seen in any location or new left bundle branch
block on the index or qualifying electrocardiogram with at least
one positive cardiac biochemical marker of necrosis (including
troponin measurements, whether qualitative or quantitative). In
cases of non-ST segment elevation myocardial infarction at least
one positive cardiac biochemical marker of necrosis without new
ST segment elevation seen on the index or qualifying electrocar-
diogram had to be present. Unstable angina was diagnosed when
serum biochemical markers indicative of myocardial necrosis
were within the normal range. Patients originally admitted
because of unstable angina but in whom myocardial infarction
developed during the hospital stay were classified as having a
myocardial infarction.
We analysed regional differences according to the distribu-
tion of centres in four geographical regions: Australia, New Zea-
land, and Canada (which were grouped together because they
exhibited similar practice patterns with regards to the use of
invasive procedures), Argentina and Brazil, Europe, and the
United States.
Statistical analysis
We expressed categorical variables as frequencies and percent-
ages and continuous variables as medians (interquartile range).
We assessed differences in demographics, clinical characteristics,
and outcomes between patients who were admitted to hospitals
with or without access to a catheterisation laboratory using 2
tests for categorical variables and Wilcoxon rank sum or
Kruskal-Wallis tests for continuous variables. Multiple logistic
regression was used to examine the association between first
admission to a hospital with catheterisation facilities or a hospi-
tal without such facilities and in clinical outcomes of major
bleeding, stroke, and mortality, with adjustment for age, sex, Kil-
lip class (clinical estimate of severity of infarct), heart rate, systo-
lic blood pressure, diastolic blood pressure, cardiac arrest at
presentation, history of diabetes, previous myocardial infarction,
stroke, positive stress test, percutaneous coronary intervention,
coronary artery bypass graft, hypertension, and geographical
region.9 Cox regression was used to examine the association
between availability of catheterisation facilities at the hospital of
first admission and mortality at 30 days and six months. We also
examined reinfarction at six months after hospital discharge.
The statistical analysis was performed with SAS software, version
8.1.
Results
Study population
We analysed data from 28 825 patients with acute coronary syn-
drome enrolled between April 1999 and March 2003 from 106
hospitals in 14 countries. Baseline risk factors, use of percutane-
ous coronary intervention and coronary artery bypass graft, and
clinical outcomes were stratified according to the presence or
absence of a catheterisation laboratory. The crude model for
death at 30 days and at six months was based on data from
28 371 (98%) patients, while the adjusted model was based on
data from 25 402 (88%) patients. We collected data on
myocardial infarction after discharge up to six months as of June
2000 and in 15 205 patients.
Baseline clinical characteristics and revascularisation
procedures
We analysed baseline characteristics of the patient cohort
according to the capability of the admitting hospital to carry out
cardiac catheterisation (table 1). Most patients in this analysis
(77%) were admitted to hospitals with catheterisation facilities
with a consistent pattern across different regions (79% in the
United States, 76% in Europe, 66% in Australia/New
Zealand/Canada, and 83% in Argentina/Brazil). The median
age of admitted patients was 66 years in units with
catheterisation facilities and 68 years in units without such facili-
ties. Overall, most patients admitted were male, but more female
patients were admitted to hospitals without catheterisation facili-
ties (32% v 37%). More patients who were first admitted to hos-
pitals without catheterisation facilities were in a poor
haemodynamic state (that is, Killip class > I).
Table 1 also shows the medical history of patients in each
type of hospital facility. A history of previous myocardial infarc-
tion and hypertension was equally prevalent in the two groups. A
history of diabetes mellitus was more common in patients
admitted to hospitals with catheterisation facilities (25% v 23%),
as was the previous use of invasive procedures.
In patients admitted to hospitals with catheterisation
facilities, percutaneous coronary intervention procedures and
coronary artery bypass graft during the index admission were
significantly more common than in patients first admitted to
hospitals without facilities: 41% v 4% for percutaneous coronary
intervention and 7% v < 1% for coronary artery bypass graft
(table 1). The largest difference in percutaneous coronary inter-
vention was found in Europe, with 48% in hospitals with and 2%
in hospitals without catheterisation facilities, respectively. For
coronary artery bypass graft the largest differences between hos-
pitals with and without facilities were found in the United States
(11% v 1.6%) and Argentina/Brazil (10% v 1%).
Clinical outcomes
The figure shows the observed clinical outcomes, the absolute
differences in outcome between patients first admitted to hospi-
tals with or without catheterisation facilities, and the unadjusted
and adjusted odds ratios/hazard ratios in the total acute
coronary syndrome population. Tables 2 and 3 show the results
for the diagnostic subgroups of patients with acute coronary
syndrome.
In the total population of patients with acute coronary
syndrome, and after adjustment for baseline characteristics,
medical history, and geographical region, patients first admitted
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to hospitals with catheterisation facilities were at a 14% increased
risk of death at six months. The risk of in hospital stroke or major
bleeding was also higher (53% and 94% respectively). There was,
however, a trend towards a lower risk of reinfarction after
discharge in such patients (hazard ratio 0.86, 0.69 to 1.08).
The pattern of increased risk of death at six months and
increased risk of major bleeding or stroke in hospitals with cath-
eterisation facilities remained consistent across the three
subgroups. There was a significant reduction in the risk of reinf-
arction after discharge in the patients with non-ST segment
elevation myocardial infarction (tables 2 and 3). In all hospitals,
the highest rates of stroke were observed in patients with ST seg-
ment elevation myocardial infarction, while major bleeding
complications were less common in patients with unstable
angina.
Discussion
This analysis from a large multinational observational registry
indicates that the availability of a catheterisation laboratory is
associated with more use of percutaneous coronary intervention
and coronary artery bypass graft in patients presenting with
acute coronary syndrome. Despite this, after we adjusted for
baseline variables, medical history, and geographical region,
patients admitted first to hospitals with catheterisation facilities
did not have a survival benefit but seemed to have higher rates of
major bleeding and stroke in hospital than those first admitted
to hospitals without such facilities.
Bleeding complications and strokes
The higher rates of major bleeding in hospital can be explained
by the higher rate of invasive procedures. Randomised studies of
acute coronary syndrome have shown that an invasive approach
is associated with an increase in bleeding complications (mainly
puncture related).1–4 Rates of stroke were higher in patients with
ST segment elevation myocardial infarction than in those with
non-ST segment elevation myocardial infarction or unstable
angina, with a consistent excess across the three diagnostic
groups in patients admitted to hospitals with catheterisation
Table 1 Key baseline characteristics and revascularisation procedures by
type of hospital (n=28 825)
Characteristic
Catheterisation laboratory
P valueYes No
No (%) of patients 22 096 (77) 6729 (23)
Median (interquartile
range) age (years)
66 (55-75) 68 (57-76) <0.001
No (%) of men 14 888 (68) 4232 (63) <0.001
Killip class* (%):
I 17 629 (82) 5254 (80) <0.001
(4×2 comparison)II 2745 (13) 995 (15)
III 834 (3.9) 308 (4.7)
IV 282 (1.3) 46 (0.7)
Medical history (%):
Stroke 1831 (8.4) 541 (8.1) 0.486
PCI 3818 (17) 557 (8.3) <0.001
CABG 2947 (13) 577 (8.6) <0.001
Coronary angiogram 6603 (31) 1154 (18) <0.001
Positive stress test 2291 (11) 666 (10) 0.215
Myocardial infarction 6633 (30) 2102 (31) 0.07
Hypertension 13 069 (60) 3921 (59) 0.162
Diabetes mellitus 5487 (25) 1559 (23) 0.005
ACS subgroup (%):
STEMI 7847 (36) 1986 (30) <0.001
(3×2 comparison)Non-STEMI 6991 (32) 2016 (30)
Unstable angina 7258 (33) 2727 (41)
Revascularisation (%):
PCI 8941 (41) 253 (3.9) <0.001
CABG 1554 (7.1) 46 (0.7) <0.001
ACS=acute coronary syndrome; CABG=coronary artery bypass grafting; CAD=coronary artery
disease; non-STEMI=non-ST segment elevation myocardial infarction; PCI=percutaneous
coronary intervention; STEMI=ST segment elevation myocardial infarction.
*Clinical signs of worsening left ventricular function from class I to IV.
   In hospital
   By 30 days
   By 6 months
Stroke in hospital
Major bleeding in
Infarction within
Death
 hospital
 6 months of discharge
5.6%
6.7%
10.4%
1.0%
3.4%
(n=11 671)
3.2%
5.4%
6.9%
9.9%
0.7%
1.7%
(n=3534)
3.9%
2.3 (-3.9 to 8.5)
-2.0 (-9.4 to 5.4)
5.0 (-4.0 to 14.0)
3.5 (1.2 to 5.9)
16.1 (12.2 to 20.0)
-7.0 (-14.4 to 0.4)
Catheterisation
facility
No catheterisation
facility
Absolute difference
per 1000 (95% CI)
1.05 (0.93 to 1.18)
1.13 (0.98 to 1.30)
0.97 (0.87 to 1.08)
1.06 (0.94 to 1.19)
1.04 (0.94 to 1.14)
1.14 (1.03 to 1.26)
1.53 (1.11 to 2.11)
1.53 (1.10 to 2.14)
1.96  (1.61 to 2.38)
1.94 (1.57 to 2.39)
0.80 (0.66 to 0.99)
0.86 (0.69 to 1.08)
Odds ratio/hazard
ratio (95% CI)
(n=22 096) (n=6729)
0.5 1.0 1.5 2.0 2.5
Lower risk in hospitals
with catheterisation
Higher risk in hospitals
with catheterisation
Clinical outcomes for all patients with acute coronary syndrome, for patients admitted to hospitals with or without catheterisation laboratory (open squares are
unadjusted ratios and closed squares are adjusted ratios)
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facilities. This excess could also be attributed to the more
frequent use of invasive procedures. The highest rates of stroke
in patients first admitted to hospitals without catheterisation
facilities were found in those with ST segment elevation myocar-
dial infarction, in whom the difference with the patients admitted
to hospitals with catheterisation facilities was also the smallest.
These findings could be explained by additional haemorrhagic
strokes due to the use of thrombolytic therapies, especially in
patients first admitted to hospitals without catheterisation facili-
ties.
No improvement with invasive facilities
In the total population of patients studied, mortality at six
months after admission was 14% higher in hospitals with
catheterisation facilities after we adjusted for differences in base-
line risk, medical history, and geographical region (figure). We
found a consistent pattern in the three diagnostic groups (tables
2 and 3).
With regard to patients with ST segment elevation
myocardial infarction, our results support the findings of the
national registry of myocardial infarction 2, and other recent
studies, that the use of intervention procedures in patients with
ST segment elevation myocardial infarction is influenced by the
interventional facilities of the admitting hospital.5 11–13 Not
surprisingly, rates of percutaneous coronary intervention and
coronary artery bypass graft seem to be significantly higher in
patients with ST segment elevation myocardial infarction who
first presented to hospitals with access to a catheterisation labo-
ratory. In patients receiving fibrinolytic therapy in the global use
of strategies to open occluded coronary arteries I trial (GUSTO-
I), those admitted to hospitals without revascularisation facilities
had similar outcomes to those admitted to hospitals with such
facilities, provided that recommended therapies were given and
patients were transferred to tertiary hospitals if necessary.14 Simi-
larly, the thrombolysis in myocardial infarction II trial (TIMI)
(n = 1461) reported no significant differences in mortality
between a conservative and an invasive approach, although the
invasive strategy was associated with higher rates of percutane-
ous coronary intervention and an increased rate of haemorrhage
than treatment in community hospitals.12 The RESCATE study11
and the European network for acute coronary treatment
(ENACT)13 reported concordant results. Meta-analyses of
randomised trials, on the other hand, have shown primary
percutaneous coronary intervention to be associated with short
and long term reductions in mortality when compared with
thrombolytic therapy, regardless of whether the patient was
transferred from a community hospital.1 However, time delays
between admission to the community hospital and first balloon
inflation in the tertiary care facility were much shorter in the
randomised studies than in the real world.15 Interpretation of
these randomised studies is further complicated because of the
selection of patients considered safe for transportation and, in
some studies, the exclusion of procedure related reinfarctions
from the primary end point.16 In our registry study the risk of
death in patients with ST segment elevation myocardial
infarction first admitted to a hospital with catheterisation
facilities did not differ significantly from that in patients admitted
to a hospital without catheterisation facilities, despite the fact
that primary percutaneous coronary intervention was more
common in the hospitals with such facilities (26% v 0.9%).
Earlier randomised studies in patients with unstable angina
and non-ST segment elevation myocardial infarction17 18 did not
show a clear benefit of a routine invasive approach, but more
recent randomised studies have reported a better clinical
outcome, mainly attributable to a reduction in the risk of
reinfarction.2–4 In the current registry, early and late mortality in
patients with unstable angina or non-ST segment elevation myo-
cardial infarction who were first admitted to hospitals without
catheterisation facilities were similar to those in patients first
admitted to hospitals with facilities, despite a lower use of
invasive procedures and a higher risk of reinfarction after
discharge. Concordant results were reported in 7984 patients
with unstable angina and non-ST segment elevation myocardial
infarction studied by the organisation to assess strategies for
ischaemic syndrome (OASIS)19 and in 791 patients with unstable
angina from the RESCATE study.20
The observed differences in mortality between patients first
admitted to hospitals with or without catheterisation facilities
were small and the odds or hazard ratios close to 1, suggesting
that an invasive approach, as often applied to patients admitted
to hospitals with catheterisation facilities, does not result in a
clear survival benefit. Although the lack of an early survival ben-
efit could be attributed to mortality related to the procedure, the
higher mortality at six months suggests that the much more fre-
Table 2 Clinical outcomes by final diagnosis of acute coronary syndrome and access to catheterisation facility. Figures are numbers (percentages) of patients
STEMI Non-STEMI Unstable angina
Access No access Access No access Access No access
No of patients 7847 1986 6991 2016 7258 2727
Died in hospital 611 (7.8) 140 (7.1) 393 (5.7) 122 (6.1) 226 (3.1) 97 (3.6)
Died by 30 days 632 (9.0) 154 (9.0) 433 (7.1) 139 (8.2) 239 (3.7) 110 (4.5)
Died by 6 months after discharge 820 (12.4) 202 (12.4) 673 (11.7) 187 (11.6) 405 (6.8) 158 (6.8)
Stroke in hospital 115 (1.5) 26 (1.3) 69 (1.0) 11 (0.6) 41 (0.6) 8 (0.3)
Major bleeding in hospital 314 (4.1) 36 (1.8)* 287 (4.2) 55 (2.8)** 128 (1.8) 25 (0.9)**
Infarction up to 6 months after discharge† 126 (3.3) 35 (3.6) 148 (4.0) 63 (6.2)** 79 (2.2) 30 (2.3)
ACS=acute coronary syndrome; non-STEMI=non-ST segment elevation myocardial infarction; STEMI=ST segment elevation myocardial infarction.
*P<0.001.
**P<0.05.
†Base numbers were 3981, 1027, 3860, 1118, 3830, and 1389, respectively.
Table 3 Adjusted odds or hazard ratios (95% confidence intervals) for
patients first admitted to hospitals with or without catheterisation facilities
according to final diagnosis of acute coronary syndrome
STEMI Non-STEMI Unstable angina
Died in hospital 1.15 (0.92 to 1.43) 1.04 (0.74 to 1.31) 0.98 (0.40 to 1.31)
Died by 30 days 1.12 (0.93 to 1.36) 0.98 (0.80 to 1.20) 0.88 (0.68 to 1.13)
Died by 6 months 1.09 (0.93 to 1.29) 1.15 (0.97 to 1.37) 1.03 (0.84 to 1.26)
Infarction (up to 6
months after
discharge)
1.02 (0.68 to 1.52) 0.72 (0.52 to 0.99) 0.85 (0.52 to 1.36)
Stroke in hospital 1.15 (0.74 to 1.80) 1.80 (0.92 to 3.55) 1.75 (0.81 to 3.80)
Major bleeding in
hospital
2.22 (1.55 to 3.18) 1.65 (1.20 to 2.26) 1.69 (1.08 to 2.64)
Non-STEMI=non-ST segment elevation myocardial infarction; STEMI=ST segment elevation
myocardial infarction.
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quent, and probably unselective, performance of revascularisa-
tion procedures in these patients is not beneficial. Although the
detection of a possible survival benefit of revascularisation may
require a longer follow up, a total reversal of the observed differ-
ence in risk of mortality is unlikely.
Comparison with randomised studies
Our results are supported by other registry data but are at vari-
ance with those of recent randomised trials. Discrepancies
between randomised trials and registries are well known but not
fully understood. One of the most important reasons is the
reluctance of investigators to include high risk patients in
randomised studies. With regard to trials in acute coronary syn-
drome it is well known that elderly and female patients are
largely under-represented.21 A more selective use of invasive pro-
cedures in the high risk patients of this registry may be partly
responsible for the favourable outcomes observed in those first
admitted to community hospitals without catheterisation
facilities. More particularly, the significantly lower incidence of
stroke and major bleeding complications can be explained by
the lower rate and more selective performance of invasive proce-
dures.
Study limitations
Notwithstanding the large number of patients, the standardised
criteria to define diagnostic subgroups and clinical outcomes,
and the quality control and audit measures, the limitations of a
registry-type study apply. Therefore, caution should be exercised
with the interpretation of our results. Though we performed
multivariable adjustments, unmeasured variables may exist that
we did not account for. In some centres, patients may have been
discharged for subsequent readmission for cardiac catheterisa-
tion and percutaneous coronary intervention, and these data
may not have been captured in our study. It was also not possible
to account for the sampling fraction in the analysis. This may
increase the uncertainty in the results beyond the reported con-
fidence intervals, although the effect is probably small.
Clinical implications
Our results do not suggest that an invasive approach to patients
with acute coronary syndrome is harmful but that a more
restrictive selective use of invasive procedures, as usually applied
to patients first admitted to a community hospital, is at least as
effective as a more liberal routine use. This analysis therefore
supports the current strategy of admitting patients with acute
coronary syndrome as rapidly as possible to the nearest hospital,
irrespective of the availability of a catheterisation laboratory, and
argues against the early routine transport of these patients to a
specialised regional tertiary care hospital with interventional
facilities.
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What is already known on this topic
In patients with acute coronary syndrome evidence from
randomised clinical trials has shown better outcomes in
those who undergo an early invasive strategy
It is unclear whether access to interventional cardiology
facilities in routine practice improves outcomes among
these patients
What this study adds
Access to cardiac catheterisation is associated with more
invasive intervention among patients with acute coronary
syndrome
After adjustment for confounders there was no increase in
survival at 30 days or six months and higher rates of major
bleeding and stroke among patients with such access than
among patients without such access
The results do not support the early routine transfer of
these patients to specialist centres with interventional
cardiology facilities
Papers
BMJ Online First bmj.com page 5 of 6
13 Gabriel Steg P, Lung B, Feldman LJ, Maggioni AP, Keil U, Deckers J, et al. Determinants
of use and outcomes of invasive coronary procedures in acute coronary syndromes:
results from ENACT. Eur Heart J 2003;24:613-22.
14 Mehta RH, Criger DA, Granger CB, Pieper KK, Califf RM, Topol EJ, et al. Patient out-
comes after fibrinolytic therapy for acute myocardial infarction at hospitals with and
without coronary revascularization capability. J Am Coll Cardiol 2002;40:1034-43.
15 Antman EM, Van de Werf F. Pharmacoinvasive therapy: the future of treatment for ST
elevation myocardial infarction. Circulation 2004;109:2480-6.
16 Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A
comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial inf-
arction. N Engl J Med 2003;349:733-42.
17 TIMI IIIB Investigators. Effect of tissue plasminogen activator and a comparison of
early invasive and conservative strategies in unstable angina and non-Q-wave myocar-
dial infarction results of the TIMI IIIB trial. Circulation 1994;89:1545-56.
18 Boden WE,O’Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al.
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned
to an invasive as compared with a conservative management strategy. Veterans Affairs
non-Q-wave infarction strategies in hospital (VANQWISH) trial investigators. N Engl J
Med 1998;338:1785-92.
19 Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L, et al. Variations between coun-
tries in invasive cardiac procedures and outcomes in patients with suspected unstable
angina or myocardial infarction without initial ST elevation. OASIS (organisation to
assess strategies for ischaemic syndromes) registry investigators. Lancet 1998;352:507-
14.
20 Lupon J, Valle V, Marrugat J, Elosua R, Seres L, Pavesi M, et al. Six-month outcome in
unstable angina patients without previous myocardial infarction according to the use
of tertiary cardiologic resources. RESCATE Investigators. Recursos Empleados en el
Sindrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol 1999;34:1947-53.
21 Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of eld-
erly persons and women in published randomized trials of acute coronary syndromes.
Jama 2001;286:708-13.
(Accepted 30 November 2004)
doi 10.1136/bmj.38335.390718.82
Universitair Ziekenhuis Gasthuisberg, Herestraat 49, Leuven, Belgium 3000
Frans Van de Werf cardiologist
University of Massachusetts Memorial Health Care, Worcester, MA 01655, USA
Joel M Gore cardiologist
University of Massachusetts Medical School, Worcester, MA 01604, USA
Kami White statistician
Research Division, Dante Pazzanese Institute of Cardiology, 04012-909, San Paulo,
Brazil
Álvaro Avezum cardiologist
Krankenhaus Düren, Düren, NRW Germany 52351
Dietrich C Gulba cardiologist
Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of
Cardiology, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada
M5B 1W8
Shaun G Goodman cardiologist
Postgraduate Medical School, Grochowski Hospital, Centrum Medycznego
Ksztalcenia Podyplomowego, Warsaw, Poland 04-073
Andrzej Budaj cardiologist
Concord Repatriation General Hospital, Coronary Care Unit, Concord, NSW,
Australia 2139
David Brieger cardiologist
Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh EH16 4SB
Keith A A Fox professor
University of Michigan Cardiovascular Center, Ann Arbor, MI 48109-0477, USA
Kim A Eagle cardiologist
Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92658-6100, USA
Brian M Kennelly cardiologist
Correspondence to: F Van de Werf frans.vandewerf@uz.kuleuven.ac.be
Amendment
This is version 2 of the paper. In this version the figure legend
has been amended to clarify that the closed squares show
adjusted ratios.
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